The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.

Results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps showed that AstraZeneca (AZN) and ...

The arrival of spring is traditionally associated with allergies, but the crisp air brought on by autumn’s cooler weather doesn’t necessarily mean everyone can take a breath of relief.

The FDA had proposed removing phenylephrine, a widely used ingredient to treat nasal congestion, from over-the-counter cold ...

This follows an extensive review that found the drug ineffective for treating nasal congestion. Oral phenylephrine, widely ...

Decongestants can help you feel less stuffed up by reducing swelling in the nasal passages, said Voigt. These include oral ...

A panel last year said it found evidence the ingredient, used in many popular medicines, did not aid with nasal congestion.

The debate about the effectiveness of phenylephrine as an oral decongestant has been going on for some time and science now ...

Share on Facebook Share on Twitter The Food and Drug Administration (“FDA”) said on Thursday that they will seek to pull the ...

by AstraZeneca and Amgen has shown significant benefits for patients with chronic rhinosinusitis with nasal polyps (CRSwNP), ...

Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...

A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...